Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05733000CT.gov CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | — | Recruiting | — | — | — |
NCT00907166CT.gov A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Exocrine Pancreatic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Devimistat (this asset) | Northwestern University | P2 | CCC · 51 |
| Fluorouracilum | Northwestern University | P2/3 | BBB |
| Irinotecan | OHSU Knight Cancer Institute | P2/3 | BBB |
| Oxaliplatin | OHSU Knight Cancer Institute | P2/3 | BBB |
| Vismodegib | OHSU Knight Cancer Institute | P2 | BB |
| Capecitabine | Zhejiang University | P2 | BB |
| Vinorelbine Ditartrate | OHSU Knight Cancer Institute | P2 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2 | BB |
| Olaparib | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Exocrine Pancreatic Carcinoma cohort
Other indications for Devimistat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P1/2 | CCC · 51 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | CCC · 51 |
| Malignant Pancreatic Neoplasm | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Devimistat in Exocrine Pancreatic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/devimistat-exocrine-pancreatic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →